MEK inhibitors as a targeted therapy approach to overcome resistance in Ph+ ALL cell line with PTPN11 mutations. Poudel G, Asari K, Yeung DT, White DL, Hughes TP, Pagani IS.
- Pagani, I. (Speaker)
Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks